公开(公告)号：US20200048183A1

公开(公告)日：2020-02-13

申请号：US16606845

申请日：2018-04-23

Applicant: THE UNIVERSITY OF WARWICK

Inventor： Gregory Leonard CHALLIS ,  Xinyun JIAN ,  Christian HOBSON ,  Joleen Solange Liesbet MASSCHELEIN

IPC: C07C69/757 ,  C07D309/10 ,  C07C271/12

Abstract: The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NRx (where R* is either H or C1-3 alkyl, e.g. CH3); R1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R1 is an optionally substituted straight-chained or branched C1-6 alkyl group (e.g. C1-3 alkyl group); R2 is H, F, Cl, Br, I or CH3; R3 is H or OH; R8 is a straight-chained or branched C1-8 alkyl group (e.g. a C1-6 alkyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R9 is H, F, Cl, Br or I; R4 and R5 are independently selected from H and OH, or R4 and R5 together are =0, preferably R4 is H and R5 is OH; R6 is H, F, Cl, Br, I or CH3; R7 is H and R7′ is OH, or R7 and R7′ together are =0, preferably R7 is H and R7′ is OH); and each — independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9 and C10-C11 are independently either C—C (single) or C═C (double) bonds).

公开(公告)号：US20190127313A1

公开(公告)日：2019-05-02

申请号：US16094617

申请日：2017-04-21

Applicant: THE UNIVERSITY OF WARWICK

Inventor： Gregory Leonard CHALLIS ,  Daniel John GRIFFITHS ,  Joleen Solange Liesbet MASSCHELEIN

IPC: C07C69/732 ,  C12P7/64 ,  C07C69/738 ,  C07C235/28 ,  A61K31/232 ,  C12P13/02

Abstract: The invention provides novel compounds of formula (I) and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. In formula (I), X is O, NR (where R is either H or C1-3 alkyl, e.g. CH3), or CH2; R3 is H, F, CI, Br, I, or CH3; R4 is H, or OH; R5 and R6 are independently selected from H and OH, or R5 and R6 together are ═O; R7 is H, F, CI, Br, I, or CH3; R8 is H, OH, or —OC(O)NR′2 (where each R′ is independently H or C1-3 alkyl, e.g. CH3), preferably R8 is H, OH or —OC(O)NH2; R9 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R9 is an optionally substituted straight-chained or branched C1-6 alkyl group (e.g. C1-3 alkyl group); R10 is a straight-chained or branched C1-8 alkyl group (e.g. C1-6 alkyl group), a C4-6 cycloalkyl group, or an optionally substituted aryl or heteroaryl group; and each --- independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9, C10-C11 and C18-C19 are independently either C—C (single) or C═C (double) bonds).